John Seymour, MBBS, FRACP, Peter MacCallum Cancer Centre, East Melbourne, Australia, discusses the 5-year update on the MURANO study (NCT02005471): A Phase III randomized comparison of venetoclax plus rituximab (VenR) versus standard bendamustine plus rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). With a 5-year median follow-up, the addition of venetoclax has shown durable improvements in progression-free survival (PFS) and overall survival (OS), compared to BR. Additionally, of the 83 patients that were negative for measurable residual disease (MRD) following venetoclax treatment, 32 patients remain MRD negative at 5 years, suggesting a curative potential. No new toxicity events were observed. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть